Nomura Asset Management Co. Ltd. Buys 994 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Nomura Asset Management Co. Ltd. boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 69,011 shares of the biopharmaceutical company’s stock after buying an additional 994 shares during the period. Nomura Asset Management Co. Ltd. owned approximately 0.05% of Alnylam Pharmaceuticals worth $13,209,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ALNY. Quent Capital LLC increased its position in Alnylam Pharmaceuticals by 246.0% during the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 123 shares in the last quarter. Anchor Investment Management LLC purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $38,000. Robeco Institutional Asset Management B.V. boosted its stake in Alnylam Pharmaceuticals by 155.7% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 12,513 shares during the last quarter. GAMMA Investing LLC purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $52,000. Finally, Lindbrook Capital LLC boosted its stake in Alnylam Pharmaceuticals by 37.2% during the 4th quarter. Lindbrook Capital LLC now owns 369 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 100 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 1.1 %

NASDAQ:ALNY opened at $147.76 on Monday. The business’s 50-day simple moving average is $149.37 and its two-hundred day simple moving average is $164.03. The stock has a market cap of $18.69 billion, a PE ratio of -55.13 and a beta of 0.41. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.23. The business had revenue of $494.33 million for the quarter, compared to the consensus estimate of $428.01 million. Alnylam Pharmaceuticals’s revenue was up 54.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.40) earnings per share. Sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -3.77 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on the company. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, April 8th. Morgan Stanley cut their target price on Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 13th. Chardan Capital restated a “buy” rating and issued a $225.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, May 3rd. Royal Bank of Canada restated an “outperform” rating and issued a $235.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. Finally, JPMorgan Chase & Co. raised their price target on Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the stock a “neutral” rating in a research note on Thursday, February 1st. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $216.19.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.